Olfaction in Parkinson’s Disease – A Clinical Approach

Haehner, Antje; Hummel, Thomas; Reichmann, Heinz

doi:10.17925/enr.2020.15.1.37

Cited by 2 publications

(2 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A wide range of nonmotor symptoms occur in PD, including sleep disorder, cognitive impairment, depression, and autonomic dysfunction [ 4 , 5 ]. Olfactory dysfunction is widely acknowledged as one of the major nonmotor symptoms of PD, which often occurs before motor symptoms in PD [ 6 , 7 ]. Taste impairment has also been demonstrated in PD.…”

Section: Introductionmentioning

confidence: 99%

Association between β2-Adrenoreceptor Medications and Risk of Parkinson’s Disease: A Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Background and Objective: Parkinson’s disease (PD) is a progressive neurological disorder characterized by an accumulation of Lewy bodies and degeneration of dopaminergic neurons in the substantia nigra. The treatment options currently available are only partly effective and fail to restore the lost dopaminergic neurons or slow the progression. β2-adrenoceptors (β2AR) are widely expressed in various human tissues and organs, regulate many important metabolic functions, and are targeted for treatment of various diseases. Studies have reported a link between chronic use of the β2AR antagonist propranolol and an increased risk of PD, and chronic use of β2AR agonists has been associated with a decreased risk of PD. We conducted a meta-analysis on the association between both β2AR agonist level and β2AR antagonist level and the risk of PD. Materials and Methods: A comprehensive electronic search was conducted on the databases of PubMed, ScienceDirect, ProQuest, Cochrane Library, and ClinicalKey from the start of each database until 30 June 2021. The objective was to identify prospective cohort and case–control studies that have reported on the association between β-adrenoceptor agonist level, antagonist level, and PD risk. Results: A meta-analysis of the data extracted from eight studies revealed that β2AR agonist use was associated with reduced PD risk (RR = 0.859, 95% confidence interval [CI] 0.741–0.995. p = 0.043). Compared with the control group, β2AR antagonist use was associated with an increased risk of PD (RR = 1.490, 95% CI, 1.195 to 1.857. p < 0.005). Propranolol, a type of β2AR antagonist, was related to an increased risk of PD (RR = 2.820, 95% CI, 2.618 to 3.036. p < 0.005). Conclusions: In this meta-analysis, β2AR agonists were associated with a decreased risk of PD, and β2AR antagonists were related with an increased risk of PD. However, further studies with larger sample sizes and an evaluation of the long-term effects of varying dosages of medications are needed.

show abstract

Section: Introductionmentioning

confidence: 99%

Association between β2-Adrenoreceptor Medications and Risk of Parkinson’s Disease: A Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Olfactory dysfunction as a sign of early infection indicating SARS-CoV-2 was promulgated in recent research ( 11 ) with 77 % (95 % CI 61⋅4, 89⋅2 %) of patients identified having such impairment using objective methods in a meta-analysis ( 13 ) . Similarly, olfactory impairment is a highly reliable symptom and early sign ( 14 ) in neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease ( 15 , 16 ) involving pathologic processes affecting the olfactory system prior to the onset of typical clinical manifestations. Hyposmia may be an early known pre-motor symptom in Parkinson's disease.…”

Section: Introductionmentioning

confidence: 99%

Alterations in taste and smell associated with SARS-CoV-2: an exploratory study investigating food consumption and subsequent behavioural changes for those suffering from post-acute sequelae of COVID-19

Khatri

2022

J Nutr Sci

View full text Add to dashboard Cite

Objective: To explore food consumption and subsequent behavioural changes amongst PASC suffers associated with alterations in taste and smell. Design: A qualitative study involving five focus groups. Setting: Birmingham and Leicester, England, United Kingdom. Participants: Forty-seven Post-Acute Sequelae of COVID-19 sufferers. Results: Shifts in taste and odour were very common with disgusting or unpleasant notes being perceived in many foods, including animal products rich in protein. Food consumption patterns varied affecting nutrition status, individuals weight, types of foods consumed, cooking habits, coping mechanisms, anxieties, family and social interactions. Individuals expressed the need to taste something or experience normal tastes and flavour. Low pH foods, highly processed foods which may contain large amounts of refined sugars as well as cold processed food were the preferred items for consumption. Conclusion: Olfactory dysfunction was related to the consumption of nutrients that require moderation and to the quality of life. Intervention at an early stage is necessary in order to help avoid such complications and thus, this work informs medical practitioners and health workers of the variety of food choices that are more acceptable for people suffering from altered tastes and odour perception.

show abstract

Olfaction in Parkinson’s Disease – A Clinical Approach

Cited by 2 publications

References 64 publications

Association between β2-Adrenoreceptor Medications and Risk of Parkinson’s Disease: A Meta-Analysis

Association between β2-Adrenoreceptor Medications and Risk of Parkinson’s Disease: A Meta-Analysis

Alterations in taste and smell associated with SARS-CoV-2: an exploratory study investigating food consumption and subsequent behavioural changes for those suffering from post-acute sequelae of COVID-19

Contact Info

Product

Resources

About